Brigham and Women's Hospital Received Ibogaine Grant
The $2.3 million award supports research into the safety and effectiveness of ibogaine for opioid use disorder.
Updated on Sept. 22, 2026 in Substance Abuse
Live Poll
Do you believe experimental medical treatments are worth the risks compared to established standard therapies?
In June 2026, the National Institute on Drug Abuse awarded over $2.28 million to Brigham and Women's Hospital in Boston. The grant funds research evaluating the drug for opioid use disorder, a condition for which no FDA-approved ibogaine form exists.
Why it matters
Ibogaine is currently a Schedule I substance associated with potentially fatal heart rhythm complications. Researchers must establish safety protocols before conducting human trials for opioid treatment.
The study defines a toxic dose as one where the QTc interval exceeds 500 milliseconds or increases by 20%. The current $2.28 million award covers research from June 2026 through May 2028.
The players
National Institute on Drug Abuse
This federal agency supports scientific research on drug use and its consequences to improve individual and public health.
Brigham and Women's Hospital
This major teaching hospital located in Boston is affiliated with Harvard Medical School and conducts extensive medical research.
Food and Drug Administration
This federal agency is responsible for protecting public health by ensuring the safety, efficacy, and security of human drugs and biological products.
The details
Researchers at Brigham and Women's Hospital plan to conduct inpatient dosing with continuous ECG monitoring to mitigate the risk of cardiac arrest. The project scope includes Phase 1 studies on healthy volunteers and Phase 2a trials for patients who failed to respond to buprenorphine.
Timeline
April 2026: The FDA allowed a clinical study of noribogaine for alcohol use disorder.
June 2026: The cooperative research agreement for the ibogaine study began.
May 2028: The research grant agreement is scheduled to conclude.
The Big Picture
This research follows federal directives in the April 2026 executive order on psychedelic therapy research to accelerate clinical testing. It marks a significant shift in the U.S. regulatory climate regarding substances previously restricted under Schedule I classifications.
Patients with opioid use disorder may gain access to a new treatment option if the trial demonstrates safety and efficacy. Individuals should remain aware that no legal, FDA-approved ibogaine treatment currently exists for use in the United States.
The takeaway
Ongoing research aims to determine if the therapeutic benefits of ibogaine can be realized while managing its severe cardiac risks. Prospective participants and families should await official updates regarding trial eligibility and safety outcomes.
Further reading
For more on evolving treatment research, visit our Substance Abuse section.
Source note: This article includes information reported by Medical Daily.
Live Poll
Do you believe experimental medical treatments are worth the risks compared to established standard therapies?
